Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Towards therapy using RNA interference.

Joseph M Alisky1, Beverly L Davidson

  • 1Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA.

American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice
|February 28, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temporal single-cell atlas of full-length Huntington's disease mouse model defines stage-specific signatures of corticostriatal dysfunction.

Molecular neurodegeneration·2026
Same author

Optimized AAV capsids robustly transduce airway epithelial cells.

bioRxiv : the preprint server for biology·2026
Same author

Neuroepithelial Tumor with AAV Integration after Intracisternal Magna Vector Delivery.

The New England journal of medicine·2026
Same author

Implications of the FDA's new plausible mechanism framework for the development of a personalized in vivo prime editing platform.

American journal of human genetics·2026
Same author

Temporal single-cell atlas of full-length Huntington's disease mouse model defines stage-specific signatures of corticostriatal dysfunction.

bioRxiv : the preprint server for biology·2026
Same author

CRISPR-mediated transcriptional activation as a mutation-independent therapeutic strategy for <i>SYNGAP1</i>-related intellectual disability.

bioRxiv : the preprint server for biology·2025
Same journal

Oncogenes as novel targets for cancer therapy (part IV): regulators of the cell cycle and apoptosis.

American journal of pharmacogenomics : genomics-related research in drug development and clinical practice·2005
Same journal

Using bioinformatics for drug target identification from the genome.

American journal of pharmacogenomics : genomics-related research in drug development and clinical practice·2005
Same journal

Antimycotic drug discovery in the age of genomics.

American journal of pharmacogenomics : genomics-related research in drug development and clinical practice·2005
Same journal

Cancer diagnostics: decision criteria for marker utilization in the clinic.

American journal of pharmacogenomics : genomics-related research in drug development and clinical practice·2005
Same journal

The Personalized Medicine Coalition: goals and strategies.

American journal of pharmacogenomics : genomics-related research in drug development and clinical practice·2005
Same journal

Expectations from structural genomics revisited: an analysis of structural genomics targets.

American journal of pharmacogenomics : genomics-related research in drug development and clinical practice·2005
See all related articles

Small interfering RNA (siRNA) molecules offer a powerful method for gene silencing by degrading target mRNA. This technology holds significant potential for treating various diseases and advancing molecular medicine research.

Area of Science:

  • Molecular Biology
  • Genetics
  • Biotechnology

Background:

  • Small interfering RNA (siRNA) are short RNA molecules that regulate gene expression.
  • siRNA functions by inducing the breakdown of specific messenger RNA (mRNA) sequences.
  • The precise mechanisms underlying siRNA-mediated gene silencing are still under investigation.

Purpose of the Study:

  • To explore the synthesis and application of siRNA for gene expression suppression.
  • To discuss the potential therapeutic targets and research utility of siRNA technology.
  • To highlight the challenges and future considerations for clinical applications of siRNA.

Main Methods:

  • Chemical synthesis of siRNA molecules.
  • Enzymatic digestion of larger double-stranded RNA using recombinant Dicer or RNAase III.

Related Experiment Videos

  • Gene silencing using plasmid or viral vectors for siRNA expression.
  • Exogenous delivery of siRNA to suppress target gene translation.

    • Main Results:

    • siRNA can be chemically synthesized or generated enzymatically.
    • Vector-mediated approaches can enhance the duration of gene suppression.
    • siRNA is a versatile tool for both research and potential therapeutic interventions.

    Conclusions:

    • siRNA technology presents a promising avenue for molecular medicine, with potential applications in treating viral infections, cancer, and neurodegenerative diseases.
    • Further research into the safety and efficacy of siRNA, particularly concerning off-target effects, is crucial for clinical translation.
    • siRNA's ability to suppress gene expression makes it an invaluable tool for understanding gene function.